Roundup: Mitsubishi, Cadila, Sun To Add Facilities Abroad
This article was originally published in PharmAsia News
Executive Summary
A trio of Southeast Asia companies plan major moves abroad, including Mitsubishi Tanabe Pharma's intention to build a China production facility through its Tianjin Tanabe Seiyaku subsidiary.
A trio of Southeast Asia companies plan major moves abroad, including Mitsubishi Tanabe Pharma's intention to build a China production facility through its Tianjin Tanabe Seiyaku subsidiary. Sources say Cadila Pharmaceutical is seeking a site in Astrakhan, Russia, for a $150 million facility to produce drugs for the Commonwealth of Independent States as well as Russia. (Click here for more
).
Meanwhile Sun Pharmaceutical Industries plans to set up business in Myanmar by opening a branch office to expand its presence in the once-reclusive nation. (Click here for more).
Mitsubishi's China plant is set to undergo construction in Tianjin by the end of August at a cost of $19.5 million, with operations beginning in 2016. (Click here for more).
"Mitsubishi Tanabe Pharma To Build New Plant In China" - Asahi Shimbun (Japan) (8/7/2013)